ChromaDex Co. (NASDAQ:CDXC) Short Interest Update

ChromaDex Co. (NASDAQ:CDXC) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 1,320,000 shares, an increase of 12.8% from the March 15th total of 1,170,000 shares. Approximately 3.0% of the company’s shares are sold short. Based on an average daily volume of 259,700 shares, the short-interest ratio is presently 5.1 days.

Analyst Upgrades and Downgrades

CDXC has been the subject of a number of research analyst reports. StockNews.com started coverage on shares of ChromaDex in a research report on Sunday, March 3rd. They issued a “strong-buy” rating for the company. Roth Mkm upped their target price on ChromaDex from $4.25 to $6.00 and gave the stock a “buy” rating in a research report on Tuesday, April 9th.

Hedge Funds Weigh In On ChromaDex

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Millennium Management LLC bought a new stake in shares of ChromaDex in the 2nd quarter worth about $1,275,000. Tieton Capital Management LLC raised its stake in shares of ChromaDex by 18.8% in the fourth quarter. Tieton Capital Management LLC now owns 2,913,675 shares of the company’s stock valued at $4,167,000 after acquiring an additional 461,692 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of ChromaDex by 1,004.0% in the 1st quarter. Renaissance Technologies LLC now owns 420,501 shares of the company’s stock worth $1,034,000 after acquiring an additional 382,413 shares in the last quarter. Vanguard Group Inc. grew its position in ChromaDex by 9.5% during the 1st quarter. Vanguard Group Inc. now owns 2,781,437 shares of the company’s stock worth $6,842,000 after acquiring an additional 240,414 shares during the last quarter. Finally, Gamco Investors INC. ET AL acquired a new stake in ChromaDex during the 1st quarter valued at $270,000. 15.41% of the stock is owned by institutional investors.

ChromaDex Trading Up 0.3 %

CDXC stock traded up $0.01 during trading on Tuesday, reaching $3.94. 249,892 shares of the stock were exchanged, compared to its average volume of 253,730. ChromaDex has a twelve month low of $1.25 and a twelve month high of $4.65. The stock has a 50 day simple moving average of $2.52 and a 200-day simple moving average of $1.81. The company has a market capitalization of $296.72 million, a P/E ratio of -56.28 and a beta of 1.98.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.